{
    "info": {
        "nct_id": "NCT06384261",
        "official_title": "Multicenter, Open-label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy",
        "inclusion_criteria": "* Men and women ≥18 years old\n* Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for the study and is willing to participate in the study\n* Diagnosis of AML according to ICC 2022 (with the exclusion of MDS/AML with 10-19% blasts)\n* Previously untreated AML except may have received emergency leukapheresis, hydroxyurea before study entry to control hyperleukocytosis\n* Deemed unfit for intensive chemotherapy by meeting at least 1 of the following criteria:\n\n  1. Participant is ≥75 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 OR\n  2. Participant is ≥18 to 74 years of age and has any of the following comorbidities:\n\n     1. ECOG performance status of 2 or 3\n     2. Cardiac status including any one of the following: congestive heart failure requiring treatment or ejection fraction ≤50% or chronic stable angina\n     3. Known history of diffusion capacity of lung for carbon monoxide (DLCO) ≤65% of forced expiratory volume in the first second (FEV1) ≤65%\n     4. Creatinine clearance (CrCl) ≥15 mL/min to <45 mL/min\n     5. Hepatic disorder with total bilirubin >1.5 to 3x the upper limit of normal (ULN)\n     6. Any other comorbidity that the investigators determine to be incompatible with conventional intensive chemotherapy\n* Adequate liver and renal function defined as:\n\n  1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3xULN; for participants with leukemic infiltration of the liver (documented by biopsy or imaging), AST and ALT <5xULN is permitted\n  2. Total bilirubin ≤1.5xULN, unless bilirubin rise is due to Gilbert's syndrome or of nonhepatic origin. Participants who are <75 years of age may have a bilirubin up to 3xULN.\n  3. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease [MDRD] formula). Participants who are <75 years of age may have an eGFR ≥15 mL/min/1.73 m2.\n* Women of childbearing potential (WOCBP), defined as fertile women between menarche and post menopause unless permanently sterile, must have a negative highly sensitive serum β-human chorionic gonadotropin (β-hCG) or urine pregnancy test at screening\n* Must be willing to use contraception as consistent with institutional guidelines regarding the use of contraceptive methods for participants participating in clinical studies\n\n  1. WOCBP must agree to adhere to the following birth control measures while receiving study treatment continuing to 3 months after the last dose of study drug:\n\n     1. Must be practicing a highly effective method of birth control (failure rate of <1% per year when used consistently and correctly) as determined by institutional standards\n     2. Must agree to not donate eggs (ova, oocytes) for the purposes of assisted reproduction\n     3. Must not be breastfeeding and not planning to become pregnant\n  2. Male participants who are sexually active with WOCBP, and male partners of study participants who are WOCBP, and who are not surgically or otherwise sterile must agree to adhere to the following birth control measures while receiving study treatment and for 3 months after the last dose of study drug:\n\n     1. Must agree to use a barrier method of birth control (e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam, gel, film, cream, or suppository)\n     2. Must not donate sperm\n     3. Must no plan to father a child\n* Participants with HIV infection are eligible for the trial if the following criteria are met:\n\n  1. CD4+ T-cell count ≥200 cells/μL\n  2. No prior history of AIDS-defining opportunistic infection within the past 12 months\n  3. Receiving treatment with antiretroviral therapy\n  4. Undetectable viral load within 6 months of screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Any prior treatment for AML (except those outlined in inclusion criterion #4)\n* Participant has received a hypomethylating agent (HMA) or venetoclax for MDS or myeloproliferative neoplasm\n* Leukemic involvement in the central nervous system\n* Participants with acute promyelocytic leukemia (APL)\n* ECOG performance status of 4 for participants 18 to 74 years of age and ECOG performance status of 3 or 4 for participants ≥75 years of age\n* Use of immune suppressive agents ≤4 weeks before the first administration of cusatuzumab. Participants may be included if free of systemic corticosteroids >5 days before the first administration of cusatuzumab with the exception of corticosteroids at physiologic replacement doses.\n* Received a live, attenuated vaccine within 4 weeks prior to initiation of study drug\n* Active malignancies (i.e., progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. Exceptions to this exclusion criterion include the following:\n\n  1. Nonmelanoma skin cancer treated within the last 24 months that is considered completely cured\n  2. Adequately treated breast lobular carcinoma in situ and breast ductal carcinoma in situ\n  3. Adequately treated cervical carcinoma in situ and breast ductal carcinoma in situ\n  4. History of localized breast cancer and receiving anti-hormonal agents, or history of localized prostate cancer (N0M0) and receiving androgen depravation therapy\n  5. A malignancy that is considered cured with minimal risk of recurrence\n* Any active systemic infection\n* History of prior HSCT (allogeneic or autologous transplants)\n* Active hepatitis B or C infection or other clinically active liver diseases ad defined below:\n\n  1. Seropositivity for hepatitis B is defined by a positive test for hepatitis B surface antigen (HBsAg)\n  2. Participants with resolved infection (i.e., participants who are HBsAg negative with antibodies to total hepatitis B core antigen [anti-HBc] with or without the presence of hepatitis B surface antibody [anti-HBs]) must be screened using PCR measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded.\n\n     * Participants with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR\n  3. Active hepatitis C infection as defined by being positive for a nucleic acid test for hepatitis C virus (HCV) RNA\n* Congestive hear failure severity that is New York Heart Association Class III or IV\n* Unstable angina\n* Known allergies, hypersensitivity, or intolerance to cusatuzumab, venetoclax, or azacitidine or their excipients (e.g., mannitol, an excipient of azacitidine)\n* Inability or difficulty swallowing capsules/tablets, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function\n* Any condition for which, in the investigator's opinion, participation would not be in the best interest of the participant (e.g., compromise the well-being) or physical limitations that could prevent, limit, or confound the protocol-specified assessments\n* Major surgery (e.g., requiring general anesthesia) ≤4 weeks prior to initiation of study treatment",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Known history of diffusion capacity of lung for carbon monoxide (DLCO) ≤65% of forced expiratory volume in the first second (FEV1) ≤65%",
            "criterions": [
                {
                    "exact_snippets": "Known history of diffusion capacity of lung for carbon monoxide (DLCO) ≤65%",
                    "criterion": "diffusion capacity of lung for carbon monoxide (DLCO)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 65,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "forced expiratory volume in the first second (FEV1) ≤65%",
                    "criterion": "forced expiratory volume in the first second (FEV1)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 65,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Men and women ≥18 years old",
            "criterions": [
                {
                    "exact_snippets": "Men and women ≥18 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previously untreated AML except may have received emergency leukapheresis, hydroxyurea before study entry to control hyperleukocytosis",
            "criterions": [
                {
                    "exact_snippets": "Previously untreated AML",
                    "criterion": "acute myeloid leukemia (AML) treatment history",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": "no prior treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "except may have received emergency leukapheresis, hydroxyurea before study entry to control hyperleukocytosis",
                    "criterion": "prior emergency leukapheresis or hydroxyurea",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "to control hyperleukocytosis"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of AML according to ICC 2022 (with the exclusion of MDS/AML with 10-19% blasts)",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of AML according to ICC 2022",
                    "criterion": "acute myeloid leukemia (AML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "AML according to ICC 2022"
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exclusion of MDS/AML with 10-19% blasts",
                    "criterion": "MDS/AML with 10-19% blasts",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for the study and is willing to participate in the study",
            "criterions": [
                {
                    "exact_snippets": "Must sign an informed consent form (ICF)",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "indicating that he or she understands the purpose of, and procedures required for the study",
                    "criterion": "understanding of study purpose and procedures",
                    "requirements": [
                        {
                            "requirement_type": "understanding",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is willing to participate in the study",
                    "criterion": "willingness to participate",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participant is ≥75 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 OR",
            "criterions": [
                {
                    "exact_snippets": "Participant is ≥75 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Deemed unfit for intensive chemotherapy by meeting at least 1 of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Deemed unfit for intensive chemotherapy",
                    "criterion": "fitness for intensive chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "fitness",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate liver and renal function defined as:",
            "criterions": [
                {
                    "exact_snippets": "Adequate liver ... function",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Must not be breastfeeding and not planning to become pregnant",
            "criterions": [
                {
                    "exact_snippets": "Must not be breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not planning to become pregnant",
                    "criterion": "pregnancy intention",
                    "requirements": [
                        {
                            "requirement_type": "intention to become pregnant",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Must not donate sperm",
            "criterions": [
                {
                    "exact_snippets": "Must not donate sperm",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "prohibition",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. ECOG performance status of 2 or 3",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 2 or 3",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "2",
                                "3"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. No prior history of AIDS-defining opportunistic infection within the past 12 months",
            "criterions": [
                {
                    "exact_snippets": "No prior history of AIDS-defining opportunistic infection within the past 12 months",
                    "criterion": "AIDS-defining opportunistic infection",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "past 12 months"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Must no plan to father a child",
            "criterions": [
                {
                    "exact_snippets": "Must no plan to father a child",
                    "criterion": "plan to father a child",
                    "requirements": [
                        {
                            "requirement_type": "intention",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must be willing to use contraception as consistent with institutional guidelines regarding the use of contraceptive methods for participants participating in clinical studies",
            "criterions": [
                {
                    "exact_snippets": "Must be willing to use contraception as consistent with institutional guidelines regarding the use of contraceptive methods for participants participating in clinical studies",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "consistency with institutional guidelines",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Any other comorbidity that the investigators determine to be incompatible with conventional intensive chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Any other comorbidity that the investigators determine to be incompatible with conventional intensive chemotherapy",
                    "criterion": "comorbidity",
                    "requirements": [
                        {
                            "requirement_type": "compatibility with conventional intensive chemotherapy",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "investigator determination",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Must agree to not donate eggs (ova, oocytes) for the purposes of assisted reproduction",
            "criterions": [
                {
                    "exact_snippets": "Must agree to not donate eggs (ova, oocytes) for the purposes of assisted reproduction",
                    "criterion": "egg (ova, oocyte) donation for assisted reproduction",
                    "requirements": [
                        {
                            "requirement_type": "agreement to not donate",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. WOCBP must agree to adhere to the following birth control measures while receiving study treatment continuing to 3 months after the last dose of study drug:",
            "criterions": [
                {
                    "exact_snippets": "WOCBP must agree to adhere to the following birth control measures while receiving study treatment continuing to 3 months after the last dose of study drug",
                    "criterion": "willingness to use birth control measures",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "while receiving study treatment and continuing to 3 months after the last dose of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Undetectable viral load within 6 months of screening",
            "criterions": [
                {
                    "exact_snippets": "Undetectable viral load within 6 months of screening",
                    "criterion": "viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months from screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with HIV infection are eligible for the trial if the following criteria are met:",
            "criterions": [
                {
                    "exact_snippets": "Participants with HIV infection are eligible for the trial",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. CD4+ T-cell count ≥200 cells/μL",
            "criterions": [
                {
                    "exact_snippets": "CD4+ T-cell count ≥200 cells/μL",
                    "criterion": "CD4+ T-cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "cells/μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Receiving treatment with antiretroviral therapy",
            "criterions": [
                {
                    "exact_snippets": "Receiving treatment with antiretroviral therapy",
                    "criterion": "antiretroviral therapy treatment",
                    "requirements": [
                        {
                            "requirement_type": "current treatment status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Must agree to use a barrier method of birth control (e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam, gel, film, cream, or suppository)",
            "criterions": [
                {
                    "exact_snippets": "Must agree to use a barrier method of birth control (e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam, gel, film, cream, or suppository)",
                    "criterion": "use of barrier method of birth control",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "condom with spermicidal foam/gel/film/cream/suppository",
                                "partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam, gel, film, cream, or suppository"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Male participants who are sexually active with WOCBP, and male partners of study participants who are WOCBP, and who are not surgically or otherwise sterile must agree to adhere to the following birth control measures while receiving study treatment and for 3 months after the last dose of study drug:",
            "criterions": [
                {
                    "exact_snippets": "Male participants who are sexually active with WOCBP",
                    "criterion": "male participant sexual activity with WOCBP",
                    "requirements": [
                        {
                            "requirement_type": "sexual activity with WOCBP",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "male partners of study participants who are WOCBP",
                    "criterion": "male partner of WOCBP study participant",
                    "requirements": [
                        {
                            "requirement_type": "partner of WOCBP study participant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "who are not surgically or otherwise sterile",
                    "criterion": "male sterility status",
                    "requirements": [
                        {
                            "requirement_type": "sterility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to adhere to the following birth control measures while receiving study treatment and for 3 months after the last dose of study drug",
                    "criterion": "adherence to birth control measures",
                    "requirements": [
                        {
                            "requirement_type": "agreement to adhere",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "while receiving study treatment and for 3 months after the last dose of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential (WOCBP), defined as fertile women between menarche and post menopause unless permanently sterile, must have a negative highly sensitive serum β-human chorionic gonadotropin (β-hCG) or urine pregnancy test at screening",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP), defined as fertile women between menarche and post menopause unless permanently sterile",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive status",
                            "expected_value": "of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative highly sensitive serum β-human chorionic gonadotropin (β-hCG) or urine pregnancy test at screening",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "serum β-human chorionic gonadotropin (β-hCG)",
                                "urine pregnancy test"
                            ]
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Must be practicing a highly effective method of birth control (failure rate of <1% per year when used consistently and correctly) as determined by institutional standards",
            "criterions": [
                {
                    "exact_snippets": "practicing a highly effective method of birth control (failure rate of <1% per year when used consistently and correctly) as determined by institutional standards",
                    "criterion": "method of birth control",
                    "requirements": [
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "% per year"
                            }
                        },
                        {
                            "requirement_type": "practice_status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "institutional_standard_compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Any prior treatment for AML (except those outlined in inclusion criterion #4)",
            "criterions": [
                {
                    "exact_snippets": "Any prior treatment for AML (except those outlined in inclusion criterion #4)",
                    "criterion": "prior treatment for AML",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Leukemic involvement in the central nervous system",
            "criterions": [
                {
                    "exact_snippets": "Leukemic involvement in the central nervous system",
                    "criterion": "leukemic involvement in the central nervous system",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active malignancies (i.e., progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. Exceptions to this exclusion criterion include the following:",
            "criterions": [
                {
                    "exact_snippets": "Active malignancies (i.e., progressing or requiring treatment change in the last 24 months) other than the disease being treated under study.",
                    "criterion": "active malignancies other than the disease being treated under study",
                    "requirements": [
                        {
                            "requirement_type": "activity_status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment_change_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with acute promyelocytic leukemia (APL)",
            "criterions": [
                {
                    "exact_snippets": "Participants with acute promyelocytic leukemia (APL)",
                    "criterion": "acute promyelocytic leukemia (APL)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received a live, attenuated vaccine within 4 weeks prior to initiation of study drug",
            "criterions": [
                {
                    "exact_snippets": "Received a live, attenuated vaccine within 4 weeks prior to initiation of study drug",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to initiation of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Adequately treated breast lobular carcinoma in situ and breast ductal carcinoma in situ",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated breast lobular carcinoma in situ",
                    "criterion": "breast lobular carcinoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequately treated ... breast ductal carcinoma in situ",
                    "criterion": "breast ductal carcinoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has received a hypomethylating agent (HMA) or venetoclax for MDS or myeloproliferative neoplasm",
            "criterions": [
                {
                    "exact_snippets": "Participant has received a hypomethylating agent (HMA) ... for MDS or myeloproliferative neoplasm",
                    "criterion": "hypomethylating agent (HMA) treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participant has received ... venetoclax for MDS or myeloproliferative neoplasm",
                    "criterion": "venetoclax treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for MDS or myeloproliferative neoplasm",
                    "criterion": "disease indication for prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": [
                                "MDS",
                                "myeloproliferative neoplasm"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of immune suppressive agents ≤4 weeks before the first administration of cusatuzumab. Participants may be included if free of systemic corticosteroids >5 days before the first administration of cusatuzumab with the exception of corticosteroids at physiologic replacement doses.",
            "criterions": [
                {
                    "exact_snippets": "Use of immune suppressive agents ≤4 weeks before the first administration of cusatuzumab",
                    "criterion": "use of immune suppressive agents",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "free of systemic corticosteroids >5 days before the first administration of cusatuzumab",
                    "criterion": "use of systemic corticosteroids",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of corticosteroids at physiologic replacement doses",
                    "criterion": "use of corticosteroids at physiologic replacement doses",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status of 4 for participants 18 to 74 years of age and ECOG performance status of 3 or 4 for participants ≥75 years of age",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 4 for participants 18 to 74 years of age",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "=",
                                "value": 4,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 74,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ECOG performance status of 3 or 4 for participants ≥75 years of age",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        },
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. History of localized breast cancer and receiving anti-hormonal agents, or history of localized prostate cancer (N0M0) and receiving androgen depravation therapy",
            "criterions": [
                {
                    "exact_snippets": "History of localized breast cancer",
                    "criterion": "localized breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving anti-hormonal agents",
                    "criterion": "anti-hormonal agent therapy",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of localized prostate cancer (N0M0)",
                    "criterion": "localized prostate cancer (N0M0)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving androgen depravation therapy",
                    "criterion": "androgen deprivation therapy",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Adequately treated cervical carcinoma in situ and breast ductal carcinoma in situ",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated cervical carcinoma in situ",
                    "criterion": "cervical carcinoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequately treated ... breast ductal carcinoma in situ",
                    "criterion": "breast ductal carcinoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Nonmelanoma skin cancer treated within the last 24 months that is considered completely cured",
            "criterions": [
                {
                    "exact_snippets": "Nonmelanoma skin cancer treated within the last 24 months",
                    "criterion": "nonmelanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "months ago"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "considered completely cured",
                    "criterion": "nonmelanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "cure status",
                            "expected_value": "completely cured"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery (e.g., requiring general anesthesia) ≤4 weeks prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Major surgery (e.g., requiring general anesthesia) ≤4 weeks prior to initiation of study treatment",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Seropositivity for hepatitis B is defined by a positive test for hepatitis B surface antigen (HBsAg)",
            "criterions": [
                {
                    "exact_snippets": "Seropositivity for hepatitis B is defined by a positive test for hepatitis B surface antigen (HBsAg)",
                    "criterion": "hepatitis B seropositivity",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive for hepatitis B surface antigen (HBsAg)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unstable angina",
            "criterions": [
                {
                    "exact_snippets": "Unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any condition for which, in the investigator's opinion, participation would not be in the best interest of the participant (e.g., compromise the well-being) or physical limitations that could prevent, limit, or confound the protocol-specified assessments",
            "criterions": [
                {
                    "exact_snippets": "Any condition for which, in the investigator's opinion, participation would not be in the best interest of the participant (e.g., compromise the well-being)",
                    "criterion": "any condition affecting participant's best interest",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion",
                            "expected_value": "participation not in best interest"
                        }
                    ]
                },
                {
                    "exact_snippets": "physical limitations that could prevent, limit, or confound the protocol-specified assessments",
                    "criterion": "physical limitations affecting protocol assessments",
                    "requirements": [
                        {
                            "requirement_type": "impact on protocol assessments",
                            "expected_value": [
                                "prevent",
                                "limit",
                                "confound"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "2. Cardiac status including any one of the following: congestive heart failure requiring treatment or ejection fraction ≤50% or chronic stable angina",
            "criterions": []
        },
        {
            "line": "2. Participant is ≥18 to 74 years of age and has any of the following comorbidities:",
            "criterions": []
        },
        {
            "line": "4. Creatinine clearance (CrCl) ≥15 mL/min to <45 mL/min",
            "criterions": []
        },
        {
            "line": "5. Hepatic disorder with total bilirubin >1.5 to 3x the upper limit of normal (ULN)",
            "criterions": []
        },
        {
            "line": "1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3xULN; for participants with leukemic infiltration of the liver (documented by biopsy or imaging), AST and ALT <5xULN is permitted",
            "criterions": []
        },
        {
            "line": "3. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease [MDRD] formula). Participants who are <75 years of age may have an eGFR ≥15 mL/min/1.73 m2.",
            "criterions": []
        },
        {
            "line": "2. Total bilirubin ≤1.5xULN, unless bilirubin rise is due to Gilbert's syndrome or of nonhepatic origin. Participants who are <75 years of age may have a bilirubin up to 3xULN.",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "* History of prior HSCT (allogeneic or autologous transplants)",
            "criterions": []
        },
        {
            "line": "5. A malignancy that is considered cured with minimal risk of recurrence",
            "criterions": []
        },
        {
            "line": "2. Participants with resolved infection (i.e., participants who are HBsAg negative with antibodies to total hepatitis B core antigen [anti-HBc] with or without the presence of hepatitis B surface antibody [anti-HBs]) must be screened using PCR measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded.",
            "criterions": []
        },
        {
            "line": "* Any active systemic infection",
            "criterions": []
        },
        {
            "line": "* Participants with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR",
            "criterions": []
        },
        {
            "line": "* Congestive hear failure severity that is New York Heart Association Class III or IV",
            "criterions": []
        },
        {
            "line": "3. Active hepatitis C infection as defined by being positive for a nucleic acid test for hepatitis C virus (HCV) RNA",
            "criterions": []
        },
        {
            "line": "* Known allergies, hypersensitivity, or intolerance to cusatuzumab, venetoclax, or azacitidine or their excipients (e.g., mannitol, an excipient of azacitidine)",
            "criterions": []
        },
        {
            "line": "* Inability or difficulty swallowing capsules/tablets, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function",
            "criterions": []
        },
        {
            "line": "* Active hepatitis B or C infection or other clinically active liver diseases ad defined below:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}